Transactiva Inc. is a research-based company working on pharmaceutical biotechnologies.
Established in 2001 by research scientists with a long experience in the field of molecular biology, genetic engineering and rare disease, Transactiva is located at the “L. Danieli ” Science and Technology Park of Udine, north-east of Italy.
The company represents a R&D center of therapeutic molecules whose production cannot be achieved by chemical synthesis, thus requiring innovative biosynthetic processes. The company is looking for new therapeutic possibilities through the development of advanced systems for the production of biopharmaceuticals using green bioreactors, a technology known as “Molecular Farming“.
The main activities carried out in Transactiva are:
- pharmaceutical research with particular emphasis to the applications of recombinant DNA technology in higher plants;
- development of novel platforms for the synthesis, accumulation and storage of drugs in plant tissues;
- molecular farming of pharmaceutical proteins for the therapy of tumors and orphan diseases;
- production of drugs and related technical reagents (enzymes, antibodies, polymers, etc.).
A leading position has been gained in molecular farming of therapeutic proteins in plants. Transactiva interfaces with pharmaceutical industries with large production facilities and a consolidated marketing and trading management. Accordingly, Transactiva can be considered a research-based Company of service to industry.
The use of transgenic plants as an industrial system for pharma production has many advantages over other systems. Those widely recognized are the high transformation efficiency, the low capital investment and running costs, the rapid scale-up of production and the remarkable safety due to the cancellation of the contamination risk by human pathogens such as viruses and mycoplasmas.
Relevant experience and skills in the genetic engineering of plants are present in Transactiva. A range of proprietary expression vectors have been developed for the constitutive, seed-specific or light-induced synthesis of therapeutic proteins in plants. These vectors are used in combination with reliable transformation and regeneration protocols for the constitution of transgenic plant populations and the subsequent selection of productive lines.
All proteins produced so far by Transactiva, including those glycosylated and with a complex tertiary structure, were found to be pharmacologically active and characterized by a high level of bioequivalence as compared to their human counterparts. The company is also engaged to increase the expertise in the field of downstream processing of drugs from plant tissues through the definition of industrially-scalable protein recovery and purification systems.
Research levels are kept consistently high through several contacts with European and US research centers and international scientific advising. Transactiva is working with European pharma industries and has already produced drug lots according to GMP which have been pharmacologically and toxicologically tested.